CD274 and breast cancer: The data obtained concerning increased PD-L1 expression together with gene expression changes as a consequence of CM-1758 treatment in vitro prompted us to study in vivo the effects of CM-1758 combined with anti-PD-L1 using a double knock-out (PtenF/F, Trp53F/F; DKO) immunocompetent BC mouse model.